These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10200826)

  • 1. Symptomatic hypocalcaemia following intravenous pamidronate in cancer patients.
    Chong G; Hoang T; Davis ID
    Aust N Z J Med; 1999 Feb; 29(1):96-7. PubMed ID: 10200826
    [No Abstract]   [Full Text] [Related]  

  • 2. Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
    Cömlekçi A; Biberoglu S; Hekimsoy Z; Okan I; Pişkin O; Sekeroglu B; Alakavuklar M
    Intern Med; 1998 Apr; 37(4):396-7. PubMed ID: 9630201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
    Sims EC; Rogers PB; Besser GM; Plowman PN
    Clin Oncol (R Coll Radiol); 1998; 10(6):407-9. PubMed ID: 9890546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptomatic hypocalcemia after intravenous pamidronate.
    McIntyre E; Bruera E
    J Palliat Care; 1996; 12(1):46-7. PubMed ID: 8857248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports.
    Champallou C; Basuyau JP; Veyret C; Chinet P; Debled M; Chevrier A; Grongnet MH; Brunelle P
    J Pain Symptom Manage; 2003 Feb; 25(2):185-90. PubMed ID: 12590034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate.
    Jodrell DI; Iveson TJ; Smith IE
    Lancet; 1987 Mar; 1(8533):622. PubMed ID: 2881152
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy.
    De Schepper J; de Pont S; Smitz J; De Coster D; Schots R; Otten J
    Eur J Pediatr; 1999 Sep; 158(9):765-6. PubMed ID: 10485313
    [No Abstract]   [Full Text] [Related]  

  • 8. Electrocardiographic Q-Tc prolongation associated with infusion of intravenous pamidronate disodium.
    Varma N; Kerrigan GN
    Postgrad Med J; 1993 Jun; 69(812):497-8. PubMed ID: 8208655
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
    Kutluk T; Akyüz C; Yalçin B; Varan A; Büyükpamuküçu M
    Med Pediatr Oncol; 1998 Jul; 31(1):39. PubMed ID: 9607431
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.
    Mishra A; Wong L; Jonklaas J
    Endocrine; 2001 Mar; 14(2):159-64. PubMed ID: 11394632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute gait disturbance associated with pamidronate infusion.
    Karapetis CS; Kotasek D; Norman JE; Sage RE
    Aust N Z J Med; 1997 Dec; 27(6):719-20. PubMed ID: 9483250
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypocalcaemia after intravenous bisphosphonate: lesson to be learnt.
    Fergus C
    BMJ; 2004 Jun; 328(7453):1439; author reply 1439-40. PubMed ID: 15191991
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose intravenous pamidronate for metastatic bone pain.
    Purohit OP; Anthony C; Radstone CR; Owen J; Coleman RE
    Br J Cancer; 1994 Sep; 70(3):554-8. PubMed ID: 8080746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocalcaemia after intravenous bisphosphonate: read the product information first.
    Breay S
    BMJ; 2004 Jun; 328(7453):1439; author reply 1439-40. PubMed ID: 15191992
    [No Abstract]   [Full Text] [Related]  

  • 15. Prolonged hypocalcaemia after pamidronate infusion in Riedel's thyroiditis associated hypoparathyroidism.
    Boumans D; de Vries PA; Rikken NE; Laverman GD
    Neth J Med; 2013 Oct; 71(8):442-3. PubMed ID: 24127509
    [No Abstract]   [Full Text] [Related]  

  • 16. Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
    Tyrrell CT; Bruning PF; May-Levin F; Rose C; Mauriac L; Soukop M; Ford JM
    Eur J Cancer; 1995 Nov; 31A(12):1976-80. PubMed ID: 8562151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypocalcaemia after intravenous bisphosphonate: adjuvant bisphosphonate is not currently accepted practice.
    Palmieri C; Dhillon T; Coombes C; Vigushin D
    BMJ; 2004 Jun; 328(7453):1439; author reply 1439-40. PubMed ID: 15191993
    [No Abstract]   [Full Text] [Related]  

  • 19. Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature.
    Kreutle V; Blum C; Meier C; Past M; Müller B; Schütz P; Borm K
    Swiss Med Wkly; 2014; 144():w13979. PubMed ID: 24964073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
    Coleman RE; Houston S; Purohit OP; Rubens RD; Kandra A; Ford J
    Eur J Cancer; 1998 May; 34(6):820-4. PubMed ID: 9797692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.